DeepMed Research

HEALTHPARTNERS INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Saline
Drug: Insulin glulisine

First Posted Date: 2011-09-19

Last Posted Date: 2015-10-19

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 12

Registration Number: NCT01436045

Locations: 🇺🇸
HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care, St. Paul, Minnesota, United States

Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk

Not Applicable

Completed

Conditions: Hyperlipidemia
Cardiovascular Diseases
Cardiovascular Risk Factor
Diabetes
Smoking
Hypertension

Interventions: Other: Prioritized Clinical Decision Support

First Posted Date: 2011-08-19

Last Posted Date: 2018-09-21

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 7914

Registration Number: NCT01420016

Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Terminated

Conditions: Eating Disorder
Type I Diabetes Mellitus Without Complication

First Posted Date: 2011-07-11

Last Posted Date: 2015-11-26

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 1

Registration Number: NCT01390636

Locations: 🇺🇸
Melrose Institute, Minneapolis, Minnesota, United States

Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition

Completed

Conditions: Diabetic Blood Glucose Monitoring
Diabetes Mellitus, Type 2

First Posted Date: 2011-07-11

Last Posted Date: 2015-11-26

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 27

Registration Number: NCT01390610

Locations: 🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States

Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder

Phase 4

Withdrawn

Conditions: Anxiety in Those Patients With Anorexia Nervosa
Eating Disorder Not Otherwise Specified, BMI (<=18)

Interventions: Other: Placebo
Drug: Hydroxyzine
Drug: hydroxyzine HCL

First Posted Date: 2011-06-14

Last Posted Date: 2016-11-15

Lead Sponsor: HealthPartners Institute

Registration Number: NCT01372670

Locations: 🇺🇸
Melrose Institute, Minneapolis, Minnesota, United States

Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

Not Applicable

Completed

Conditions: Type 2 Diabetes

Interventions: Device: CGM Group
Device: SMBG Group

First Posted Date: 2010-11-09

Last Posted Date: 2018-10-17

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 124

Registration Number: NCT01237301

Locations: 🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States

The Impact of Food on Blood Sugar in People With Type 2 Diabetes

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2010-11-09

Last Posted Date: 2015-12-02

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 46

Registration Number: NCT01237314

Locations: 🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

Phase 4

Completed

Conditions: Hyperglycemia

Interventions: Drug: NPH insulin plus Complete Insulin Orders
Drug: Complete Insulin Orders

First Posted Date: 2010-08-18

Last Posted Date: 2018-06-13

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 72

Registration Number: NCT01184014

Locations: 🇺🇸
Park Nicollet Health Services Methodist Hospital, Saint Louis Park, Minnesota, United States

Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

Not Applicable

Completed

Conditions: Insulin
Diabetes

Interventions: Device: insulin dose software

First Posted Date: 2010-07-27

Last Posted Date: 2020-01-27

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 46

Registration Number: NCT01170208

Locations: 🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

Not Applicable

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Exenatide
Drug: Insulin Glargine

First Posted Date: 2010-03-18

Last Posted Date: 2017-05-23

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 60

Registration Number: NCT01089569

Locations: 🇺🇸
International Diabetes Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy